Daré Bioscience, Inc. (DARE) Fair Value 2026

DARE · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-28, Daré Bioscience, Inc. (DARE) trades at $0.73. QOC: 5.2/10. Value Trap Risk: 35/100 (LOW). 0/13 models active.

Key Facts

Ticker
DARE
Price
$0.73
Quality Score
5.2/10
Value Trap Risk
35/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give DARE?

0 Intrinsic Value Models vs. Current Price ($0.73)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Daré Bioscience, Inc. (DARE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Daré Bioscience, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About DARE?

0 of 13 models are currently active for DARE. See which stocks rank higher →

How Does DARE Rank in Biotechnology?

Among 625 Biotechnology stocks, DARE ranks #265 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Daré Bioscience, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.

Is DARE a Value Trap?

CirclFi's Value Trap algorithm assigns DARE a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Daré Bioscience, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Daré Bioscience, Inc. earns a quality score of 5.2/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every DARE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Daré Bioscience, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CBUSCibus, Inc.QOC 5.2MLECMoolec Science SAQOC 5.2CRBUCaribou Biosciences, Inc.QOC 5.2NKTXNkarta, Inc.QOC 5.2AVIRAtea Pharmaceuticals, Inc.QOC 5.2ALXOALX Oncology Holdings Inc.QOC 5.2AVTXAvalo Therapeutics, Inc.QOC 4.6XCURExicure, Inc.QOC 3.5STROSutro Biopharma, Inc.QOC 6.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CBUS · MLEC · CRBU · NKTX · AVIR · ALXO · AVTX · XCUR · STRO · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to DARE?

5 companies across all industries closest to DARE’s Quality of Company score of 5.2/10.

ELUTElutia Inc.QOC 5.2GRHIGold Rock Holdings, Inc.QOC 5.2LEELee Enterprises, IncorporatedQOC 5.2CTSOCytosorbents CorporationQOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ELUT · GRHI · LEE · CTSO · NVDA

Where Does DARE Sit in CirclFi's Biotechnology Rankings?

DARE is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Daré Bioscience, Inc.’s Valuation?

What is Daré Bioscience, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Daré Bioscience, Inc. (DARE). The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is DARE overvalued or undervalued right now?

At $0.73, 0 of 0 active models suggest DARE may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Daré Bioscience, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.2 mean for DARE?

Daré Bioscience, Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on DARE?

CirclFi analyzes DARE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is DARE a value trap in 2026?

Daré Bioscience, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Daré Bioscience, Inc. (DARE) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/DARE/ · Methodology
Primary sources for this DARE valuation
  • Financial statements: Daré Bioscience, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001401914) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for DARE as of ; valuations recomputed .